At the 71st annual American College of Cardiology (ACC) 2022 meeting, results presented for the SCORED trial will likely lead to a large market share for Lexicon Pharmaceuticals’ sodium-glucose co-transporter-inhibitor (SGLT-I) sotagliflozin (Zynquista). The therapy is currently in Phase III in the US, as physicians increasingly prescribe SGLT-2Is for patients with Type 2 Diabetes (T2D) and additional comorbidities such as cardiovascular disease (CVD) and chronic kidney disease (CKD) says GlobalData, a leading data and analytics company.

Akash Patel, Pharma Analyst at GlobalData, comments: “Sotagliflozin, with its past difficulties entering the T1D market, will likely gain approval in the US for the treatment of T2D and have successful market uptake, particularly with its additional benefits for reducing risk of CVD, Myocardial Infarction (MI), and stroke. There is increasing anticipation among physicians for therapies in the T2D space that address the complexity of comorbidities that occur including CVD, CKD, stroke, and obesity, and SGLT-2Is have proven efficacious at treating these.”

In both the patients with and without CVD, there were significant reductions in CV death, including MI, and stroke. Overall, there was a 26% risk reduction observed in the treatment arm with regard to composite of total CV deaths, hospitalizations for heart failure, and urgent heart failure visits, with early significant benefits observed across all of these areas at about 3 months.

Patel adds: “There is serious competition underway in the T2D market to gain dominance in the SGLT-2 space, with all the currently marketed inhibitors demonstrating efficacy for HF and CKD in addition to T2D. The recent data from the SCORED trial will likely support Lexicon, sotagliflozin’s manufacturer, in becoming a leading player in the SGLT-2 market.”